Martin TG, Juarros MA, Leinwand LA. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat Rev Cardiol. 2023;20:347–63. https://doi.org/10.1038/s41569-022-00806-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl J Med. 1990;322:1561–6. https://doi.org/10.1056/NEJM199005313222203.

Article  CAS  PubMed  Google Scholar 

Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084–91. https://doi.org/10.1161/HYPERTENSIONAHA.109.136655.

Article  CAS  PubMed  Google Scholar 

Chen JS, Pei Y, Li CE, Li YN, Wang QY, Yu J. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: a network meta-analysis of randomized controlled trials. J Clin Hypertens. 2020;22:2175–83.

Article  CAS  Google Scholar 

Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36:e12435. https://doi.org/10.1111/1755-5922.12435.

Article  CAS  PubMed  Google Scholar 

Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41:3421–32. https://doi.org/10.1093/eurheartj/ehaa419.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl J Med. 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038.

Article  CAS  PubMed  Google Scholar 

Brooks JE, Soliman EZ, Upadhya B. Is left ventricular hypertrophy a valid therapeutic target? Curr Hypertens Rep. 2019;21:47 https://doi.org/10.1007/s11906-019-0952-9.

Article  PubMed  Google Scholar 

Chu HW, Hwang IC, Kim HM, Park J, Choi H, Choi HM, et al. Age-dependent implications of left ventricular hypertrophy regression in patients with hypertension. Hypertens Res. 2024. https://doi.org/10.1038/s41440-023-01571-w.

Lønnebakken MT, Izzo R, Mancusi C, Gerdts E, Losi MA, Canciello G, et al. Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network). J Am Heart Assoc. 2017;6:e004152. https://doi.org/10.1161/JAHA.116.004152.

Article  PubMed  PubMed Central  Google Scholar 

Bang CN, Devereux RB, Okin PM. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A life review. J Electrocardiol. 2014;47:630–5. https://doi.org/10.1016/j.jelectrocard.2014.07.003.

Article  PubMed  Google Scholar 

Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48–54. https://doi.org/10.1161/01.cir.97.1.48.

Article  CAS  PubMed  Google Scholar 

Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the life study. Circulation. 2007;116:700–5. https://doi.org/10.1161/CIRCULATIONAHA.106.666594.

Article  PubMed  Google Scholar 

Grajewski KG, Stojanovska J, Ibrahim EH, Sayyouh M, Attili A. Left ventricular hypertrophy: evaluation with cardiac MRI. Curr Probl Diagn Radio. 2020;49:460–75. https://doi.org/10.1067/j.cpradiol.2019.09.005.

Article  Google Scholar